MC-21, was established in 1998 to develop and administer unique, tailored, and flexible pharmacy programs for corporations, managed care organizations, unions, government agencies, and others. We work very closely with our clients to achieve their goals by integrating all pharmacy benefit components: clinical services, care management, technology, rebates, and administrative support. We are the only full service Pharmacy Benefit Management (PBM) entity in the US certified by the National Minority Supplier Development Council. In just ten years of operations we have achieved the servicing of 40% of the population in the Commercial/Managed Care Organization, private, Medicare/Medicaid markets in Puerto Rico. Moreover, MC-21 successfully processes over 28 million claims annually, which represents over $1.0 billion in drug spend, while managing over 500 different pharmacy plan designs. As of today, our pharmacy network includes over 52,000 independent and major chain pharmacies throughout the US and Puerto Rico.

CytoImmune Therapeutics, LLC develops novel, coordinated immunotherapy solutions for patients. Our CoalesceNT™ platform harnesses the power of bispecific antibody (biAb) and chimeric antigen receptor (CAR) technology to coordinate an immune response with both natural killer (NK) and T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic immune response that reflects natural immunity.